Breaking Barriers 7 Explosive Stocks Shattering Resistance Levels

 StocksRunner
 
  StocksRunner
 
Follow  Message
 
 
 
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
 

•  07 Jun 2025
 

The market is speaking, are you listening? Several stocks have just broken through critical resistance levels, potentially signaling major upward momentum.

$PHAT Phathom Pharmaceuticals has exploded through its resistance at $5.33, soaring to $8.92 after the FDA granted a crucial petition regarding Voquezna exclusivity. With intraday highs reaching $12.32, this stock has demonstrated extraordinary strength, with volume surging to 51.76M—over 26 times its average. While the stock lacks earnings (EPS of -$5.24), this regulatory catalyst has completely transformed its technical picture.

$AGEN Agenus has pushed through resistance at $5.86, closing at $5.95 with double its average volume. The RSI indicates overbought conditions, suggesting potential for a pullback, but the stock's momentum is undeniable. Having traded as low as $1.38 in the past year, this biotech play has shown remarkable recovery potential despite negative earnings.

$APLD Applied Digital has cleared resistance at $13.16, settling at $13.86 with massive volume, 173.48M shares versus its 58.17M average. The stock touched $15.42 intraday, representing its 52-week high. With a beta of 5.90, APLD offers high volatility and potentially outsized returns, though its negative EPS (-$1.37) indicates the company is still in growth mode.

$AKBA Akebia Therapeutics has broken above $3.68 resistance, closing at $3.97 after seven straight days of price increases. Volume has been healthy at 7.54M shares, well above its 4.96M average. Trading near its intraday high of $4.00, which also marks its 52-week high, AKBA shows strong momentum despite negative earnings.

$HBM Hudbay Minerals has pushed through $9.39 resistance to close at $9.62 after five consecutive up days. With above-average volume of 11.68M shares and a relatively modest beta of 1.60, HBM offers a potentially less volatile play among these breakouts. The stock is trading near its 52-week high of $9.86, suggesting continued strength.

$RKLB Rocket Lab has cleared resistance at $28.87, closing at $28.92 with nearly double its average volume. The stock has benefited from multiple catalysts, including increased commercial demand for launch services and potential opportunities from the reported Trump-Musk tensions. With the space economy projected to grow substantially from its current $500 billion valuation, RKLB position in this sector makes it particularly interesting despite negative earnings.

$CRSP CRISPR Therapeutics has broken through $39.95 resistance, closing at $41.86 after five consecutive up days. The stock has established a new resistance level at $43.60, with volume more than doubling its average. As the company behind groundbreaking CRISPR-Cas technology, its recent announcement about the first patient dosed with GEB-101 (the world's first in vivo CRISPR-Cas ribonucleoprotein-based genome editing therapy) has reignited interest in this biotech innovator.

Strategic Considerations When trading breakouts, consider these critical factors:
1. Confirmation is key - Wait for a stock to close above resistance on above-average volume before entering.
2. Mind the RSI - Stocks like AGEN with overbought conditions may need to consolidate before continuing higher.
3. Volume validation - The strongest breakouts (like PHAT and APLD) show massive volume expansion, confirming institutional interest.
4. Consecutive up days - Stocks like AKBA and HBM with multiple consecutive green days demonstrate persistent buying pressure.
5. New resistance becomes support - Previous resistance levels often become support on pullbacks, offering potential entry points with defined risk.